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QRM CONSIDERATIONS FOR MEDICINES REGULATORY AUTHORITIES
ABSTRACTRisk management principles are effectively utilized in many areas of business and government including finance, insurance, occupational safety,public health, pharmacovigilance, and by agencies regulating these industries. In regulatory perspective it is used to assist with resource allocationincluding, for example, inspection planning and frequency, and inspection and assessment intensity. It is also helps evaluate the significance ofproducts; like quality defects, potential recalls and inspectional findings. It is also find its potential; appropriateness and type of postinspectionregulatory follow-up To identify risks that should be communicated between inspectors and assessors to facilitate better understanding of howrisks can be or are controlled (e.g., parametric release, Process Analytical Technology (PAT)). In short QRM has become a mandatory regulatoryrequirement towards healthcare organizations.
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INTRODUCTIONSince last few years Quality Risk Management (QRM) has become amandatory regulatory requirement for Pharmaceuticals. QRM is anoverall and continuing process of minimizing risks to productquality throughout its life-cycle in order to optimize its benefit andbalance the risk. It is a systematic process for the evaluation, control,communication and review of risks to the quality of the medicinalproduct. It pertains scientific and practical decisions whenintegrated into quality systems, examples of quality systems includeValidation, Quality Defects - Investigation, Auditing, Inspection,Documentation, Training etc. Quality Risk Management principlesare effectively utilized in many areas including business, insurance,work related safety, public health, pharmacovigilance, and byagencies regulating these industries. A key principle of theseguidelines is that all medicines regulatory authorities (MRAs),manufacturing sites in developing countries and API manufacturersshould demonstrate, wherever appropriate, application of QRMthroughout the product life-cycle for development andmanufacturing facilities. Inspectors will review this QRM system aspart of the quality systems section of the inspection (along withcomplaints, recalls, deviations, product quality reviews and others).Equally, it is recommended that QRM be applied by the MRAsthemselves (reviewers and inspectorates) as there are clear benefitsof a QRM-based review and inspection plan. For example, inspectorscan allocate time and resources commensurate with the perceivedsignificance of risk in any given situation and can be pragmaticregarding the level of scrutiny and degree of formality required.
QRM application to inspection strategy [1-5]
Risk management in inspectionsThe inspection section or unit of an MRA should operate within awritten, implemented quality management system. SOPs should befollowed for activities including (but not limited to) inspectionplanning, review of corrective and preventive actions afterinspections and complaint handling and investigation. Whereappropriate, the procedures and activities during inspection shouldbe in line with the principles of QRM. The unit should have a riskmanagement plan that describes the philosophy, approach,procedures and implementation of risk management. The riskmanagement plan should be reviewed and updated on a continuousbasis, or at least annually, and should cover all types of inspections(including GMP, good clinical practices (GCP), good laboratorypractices (GLP)) and other activities. Appropriate risk assessment
tools should be used in the process, and the risk assessment for asite to be inspected should be documented on a risk assessmentworksheet. Records should be maintained. A metric system shouldbe used for risk ratings, e.g. on a scale from 1 to 3.
Inspection planning and conductThe frequency and scope of inspections should be determined basedon risk assessment that covers product risk and patient risk. Riskrating should normally be done only for sites that have beenpreviously inspected. The risk assessment worksheet should becompleted after every inspection. Inspection of a site that has notbeen inspected previously may be waived only in cases where arecognition procedure exists between regulatory inspection units,and where, in addition, appropriate evidence of GXP compliance isavailable which indicates that there is no risk or an acceptably lowrisk to products and patients. Various factors should be consideredin the risk assessment exercise, and these factors may be differentfor the different types of GXP inspections. Risk factors to beconsidered depend on the type of inspection, and may include:Outcome of inspection by another regulatory authority;Outcome of the previous inspection;Complexity of the site (e.g. buildings, utilities);Complexity of the product (e.g. sterile, non-sterile); type of product(e.g. biological, low-dose); complaints and recalls;Significance of changes (e.g. equipment, key personnel);Results of product testing;Risk to the patient;Complex route of synthesis (API);Polymorphism (API);Biopharmaceutical classification of the product;Innovative or emerging technology.Risk rating of the site of inspection will be considered fordetermining number of inspectors and number of days required forthe inspection, as well as the scope of the inspection. Based onfindings and observations risk report should be prepared. It can becategorized as “critical”, “major” or “minor”. The unit should havean SOP that describes the classification process. Classification shouldbe based on risk assessment. The level of risk assigned should be in
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accordance with the nature of the observation as well as the numberof occurrences.
Corrective action and preventive action (CAPA) review, and
scheduling of routine inspectionsCAPA should be requested from a site, following an inspection. TheCAPAs should address the observations included in an inspectionreport. Based on the outcome of the inspection and the acceptabilityof the CAPA, the risk rating of the site should be reviewed andrecorded. Inspection frequency should be defined based on the riskrating. For example, the frequency can be defined as every 6, 12, 18or 24 months. (Note: The maximum time interval should be no morethan every 36 months.)
Complaint handling and investigationHandling and investigation of quality complaints should be done inaccordance with a written SOP. The scope and depth of theinvestigation (including whether a desk review or on-site inspectionwill be done) should be based on risk assessment.
Inspection of QRM at a manufacturing siteDuring inspections, inspectors should assess whether amanufacturer has appropriate skills and scientific knowledge, aswell as product and process knowledge, for the QRM procedurebeing inspected. This is also relevant where a company has made useof contracted parties. The company's QRM procedure should beappropriately detailed and should be integrated into the company’squality management system. It should cover at least the followingareas:
 It should specify the general approach to both planned andunplanned risk assessment, including scope, responsibilities,controls, approvals, management systems, applicability andexclusions.
 Personnel should have appropriate qualifications, experienceand training. Their responsibilities with regard to QRM shouldbe clearly defined.
 Senior management should be involved in the identificationand implementation of QRM principles within the company.
 The risk management procedure(s) for each area of applicationshould be clearly defined.
 Quality assurance principles should be applied to QRM-relateddocumentation, e.g. review, approval, implementation andarchiving. QRM policies and procedures should be clear and theworkflow should be systematic and conducted in a logicalorder.
 The procedure for risk management should be implemented.
 Manufacturers should identify significant risks and consider allthe relevant data from reliable sources.
 The level of effort and resources used in risk assessmentshould be appropriate to the importance of the identifiedproblem.
 Critical issues should be addressed with appropriate urgencyand formality.
 There should be a logical selection of tools for risk assessment.
 Risk acceptance criteria should be appropriate.
 Risk assessments should not underrate the severity, noroverrate detection of occurrences resulting in underestimatingpatient risk.
 The risk acceptance criteria should be appropriate for thespecific situation in question.
 Risk controls should be effective.
 The company should have a review programme to measure theeffectiveness of the measures taken.
 Risk-based decision(s) should be science-based and concordantwith the predefined acceptance criteria.
 All documentation related to the QRM activities should becompleted within a reasonable period and should be accessible.
 Risk assessments performed should be reviewed whenappropriate, and additional controls implemented whenrequired.
 Personnel should be trained and assessed in the principles ofQRM.
 Where appropriate, a team of members of personnel shouldparticipate in the QRM processes.
QRM applied to dossier review (assessment)The assessment processes of national medicines regulatoryauthorities (NMRAs) rely on QRM principles in the management ofresources (time and assessors), as well as in the management ofproduct-related risk factors. Efficient management of resourcesminimizes the risk that limited resources are not used to their besteffect, and ultimately ensures that important products are madeavailable in a timely manner. Key factors to be considered includethe prioritization of dossiers, the screening process, identification ofthe specific risk factors inherent to a given dossier or dosage form,and allocation of resources to the various sections of a dossier for agiven product. In addition, product-related risk factors must bemanaged throughout the life-cycle of the product, for example,through effective communication between assessors and inspectors,and by establishing systems for dealing with the products afterapproval. The allocation of priority to dossiers should take intoaccount the therapeutic needs of the regional population (e.g.disease occurrence, the need for paediatric formulations,combination products, or experience with innovative or emergingtechnology) and the availability of medicines on the market.Prioritization should be a dynamic process to enable it toaccommodate emerging issues such as pandemics. Otherconsiderations related to prioritization based on medical need mayinclude fixed-dose combinations versus single-ingredient or co-packaged products, extended release products versus productsadministered as two or three daily doses, second-line versus first-line products, flexible dosage forms such as dispersible tablets andvariable dose products such as oral liquids. The screening processexamines the completeness of a dossier. Screening ensures that onlythose dossiers that meet minimum standards for completeness canenter into the full assessment process. Insufficient screeningprocesses allow lower quality dossiers to be accepted for review,thus significantly increasing assessment time. Identification ofdossier-related and product-related risk factors allows for theallocation of appropriate resources to specific dossiers. Possible riskfactors include: the experience and track record of the manufacturer,narrow therapeutic range products, sterile versus non-sterile APIsand products; API-related considerations such as use of semi-synthetic and fermentation products, complex routes of synthesis,polymorphism, isomerism and potential genotoxic impurities; andproduct-related considerations such as the use of novel excipients,the complexity of the formulation, single-ingredient versus fixed-dose combinations, and special delivery systems (e.g. modifiedrelease, transdermal products, and inhalation products). Once riskfactors have been identified, resources should be allocated tominimize risk. For example, assessors with expertise related to theproduct-related risk identified should be assigned to assess thedossier whenever possible. When resources allow, the assessorsmay be organized according to specialization, assigning assessors tovarious product categories (e.g. generic products, sterile products,solid oral dosage forms, or special delivery systems). This canfacilitate the development of expertise in key areas and promoteconsistency of review, as well as ensuring that products requiringspecialized knowledge are identified and assessed by those with theappropriate expertise. Where a high level of risk is identified for adossier, the more experienced assessors need at least to be availableon a consultation basis. The risk level associated with a dossier maychange during the course of assessment. For example, rejection ofthe bioequivalence study will result in additional time required toconduct and assess additional studies and associated additionalquality information. In such a scenario the risk relates both to theuse of additional resources and to an increased risk that the overallproduct quality may be poor.Allocation of resources to various aspects or sections of the dossieris an important QRM consideration, in order to ensure that theresources used are commensurate with the risk level. Anunderstanding of the relative criticality of dossier sections or aspectsis necessary for efficient use of resources. All aspects of the dossierare important to achieve overall quality, safety and efficacy; howeversome areas are inherently more critical from a risk perspective and
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warrant more attention in the assessment process. Examples includethe clinical reviews bioavailability reviews, API synthesis,specifications and stability studies, FPP manufacturing details,pharmaceutical development studies including biowaiverjustification, process validation, specifications and stability studies.An example applicable to most simple solid oral products is thatmore time should be allocated to the review of manufacturing stepsprior to packaging than to reviewing the packaging process. Duringthe assessment process there should be a standard procedure forcommunicating to the inspectors those issues identified which mayrequire consideration during inspection. After approval of a product,QRM principles should be applied to evaluate the impact of proposedvariations or changes. Clear guidelines that outline possible post-approval changes and assign an associated risk level are an effectivemeans to achieve this.
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